ImaginAb, Inc.

ImaginAb, Inc.

ImaginAb, Inc.

Date Founded




Type of Company


Employees (Worldwide)

11 - 50


Medical Products & Equipment
IT Consulting & Services
Hospitals & Patient Services
Holding Companies
Medical Support Services

Company Description

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Contact Data
Trying to get in touch with decision makers at ImaginAb, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees



Chief Executive & Operating Officer

Chief Business Officer

Vice President, Regulatory & Quality Assurance

Vice President, Manufacturing

Vice President, Imaging Sciences

Senior Scientist

Media Relations Contact

Board of Directors

Professor of Practice at King's College London

Co-Founder at ImaginAb, Inc.

Co-Founder at Cycad Group LLC

Partner at Nextech Invest AG

Chief Executive & Operating Officer at ImaginAb, Inc.

Paths to ImaginAb, Inc.
Potential Connections via
Relationship Science
ImaginAb, Inc.
Recent Transactions
Details Hidden

ImaginAb, Inc. raised money in a private placement transaction

Details Hidden

ImaginAb, Inc. raised money in a private placement transaction

Details Hidden

ImaginAb, Inc. raised money in a private placement transaction

Advisors & Consultants

Chief Business Officer at ImaginAb, Inc.


Managing Director at Westwicke Partners LLC


Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Details Hidden

The Parker Institute For Cancer Immunotherapy is an American private company located in San Francisco, CA, that operates cancer research. Jeffrey A. Bluestone is the CEO, in this role since 2015.The company says this about itself: The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians and industry partners to build a smarter and more coordinated cancer immunotherapy research effort. The Parker Institute is an unprecedented collaboration between the country's leading immunologists and cancer centers. The program started by providing institutional support to six academic centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center. The institute also provides programmatic support for top immunotherapy investigators, including a group of researchers at Dana-Farber Cancer Institute, Robert Schreiber, Ph.D., of Washington University School of Medicine in St. Louis, Nina Bhardwaj, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai, and Phil Greenberg, M.D., of the Fred Hutchinson Cancer Research Center.

Details Hidden

ACM manages the Adage Capital Partners Fund (ACP). The firm seeks to achieve its objective through stock selection based primarily on intra-industry fundamental analysis with a dedicated focus on intra-industry valuation methodologies. Primary research is a central component of their investment process. ACM utilizes a staff of portfolio managers and equity analysts dedicated to tracking specific sectors represented within the Index that utilize a stock valuation methodology designed for each specific sector in selecting the investments of ACP. The firm currently utilizes one non-industry specific analyst, focusing on risk arbitrage opportunities for ACP. They may employ additional analysts and/or portfolio managers in the future, focusing on non-industry specific methodologies for identifying investments for ACP, and in connection with such methodologies ACM may cause ACP engage in additional types of investments, such as leveraged trading and/or risk arbitrage or other event driven trading.

Details Hidden

Nextech is an active manager which invests in selected life science companies in Europe, Asia and the US. They have a particular focus on cancer therapy. They help build successful business ventures from life science innovations originating in academia and industry and also support the incubation of strong research teams.The firm seeks to invest in well managed companies with proprietary, cutting-edge products which understand the market and their competitors. Their investment approach aims to take drug assets in the preclinical stage and build their value by demonstrating clinical efficacy.Nextech mainly acts as lead investor in Europe and co-invests in OECD countries outside of Europe. They make investments based on recommendations from their Scientific Advisory Board, which assesses the scientific concept and the drug development plan.The firm aims to exit their investments through trade sales and IPOs after demonstrating efficacy or comparable benefits in human studies.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ImaginAb, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ImaginAb, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and ImaginAb, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15